Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) vs. Adicet Bio (NASDAQ:ACET) Head-To-Head Analysis

Adicet Bio (NASDAQ:ACET) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Profitability

This table compares Adicet Bio and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adicet Bio	N/A	-80.35%	-65.44%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Institutional & Insider Ownership

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Adicet Bio has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Earnings & Valuation

This table compares Adicet Bio and Lakefront Biotherapeutics American Depositary Shares”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adicet Bio	N/A	N/A	-$116.80 million	($14.90)	-0.60
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.60	$363.05 million	($1.41)	-21.72

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Adicet Bio. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Adicet Bio and Lakefront Biotherapeutics American Depositary Shares, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adicet Bio	1	1	5	1	2.75
Lakefront Biotherapeutics American Depositary Shares	1	6	0	1	2.12

Adicet Bio presently has a consensus price target of $48.80, suggesting a potential upside of 446.17%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, suggesting a potential upside of 19.16%. Given Adicet Bio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Adicet Bio is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Summary

Adicet Bio beats Lakefront Biotherapeutics American Depositary Shares on 7 of the 12 factors compared between the two stocks.

About Adicet Bio

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.